RIGL - Rigel Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5416.31M
Enterprise Value 3320.09M
Trailing P/E N/A
Forward P/E 1-7.11
PEG Ratio (5 yr expected) 1-0.12
Price/Sales (ttm)7.29
Price/Book (mrq)4.37
Enterprise Value/Revenue 35.60
Enterprise Value/EBITDA 6-4.87

Trading Information

Stock Price History

Beta (3Y Monthly) 1.26
52-Week Change 3-16.44%
S&P500 52-Week Change 36.42%
52 Week High 33.6500
52 Week Low 31.9600
50-Day Moving Average 32.3146
200-Day Moving Average 32.2950

Share Statistics

Avg Vol (3 month) 31.43M
Avg Vol (10 day) 3731.67k
Shares Outstanding 5167.19M
Float 166.71M
% Held by Insiders 10.25%
% Held by Institutions 197.74%
Shares Short (Jun 28, 2019) 413.39M
Short Ratio (Jun 28, 2019) 49.62
Short % of Float (Jun 28, 2019) 411.31%
Short % of Shares Outstanding (Jun 28, 2019) 48.01%
Shares Short (prior month May 31, 2019) 420.37M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 29/1
Last Split Date 3Jun 25, 2003

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019


Profit Margin -111.48%
Operating Margin (ttm)-116.09%

Management Effectiveness

Return on Assets (ttm)-30.53%
Return on Equity (ttm)-72.74%

Income Statement

Revenue (ttm)57.13M
Revenue Per Share (ttm)0.34
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-2.68M
EBITDA -65.68M
Net Income Avi to Common (ttm)-63.69M
Diluted EPS (ttm)-0.3850
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)127.92M
Total Cash Per Share (mrq)0.76
Total Debt (mrq)31.7M
Total Debt/Equity (mrq)33.26
Current Ratio (mrq)5.33
Book Value Per Share (mrq)0.57

Cash Flow Statement

Operating Cash Flow (ttm)-36M
Levered Free Cash Flow (ttm)-41.46M